Dr. Reddy’s Submits Auditor Review Reports for Q2 FY27 Results
Dr Reddys Laboratories Ltd · Others (Uncategorized) · 24 Oct 2026, 4:01 am
Dr. Reddy’s Submits Auditor Review Reports for Q2 FY27 Results Dr. Reddy’s Laboratories has submitted the Limited Review Reports issued by statutory auditor Deloitte Haskins & Sells LLP for its unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. The auditor issued an unmodified review conclusion under Regulation 33 of SEBI Listing Regulations, confirming compliance with Ind AS 34 and finding no material misstatements. Key consolidated entities include Aurigene Discovery Technologies, Betapharm Arzneimittel, Dr. Reddy’s Inc., and its newly incorporated Vietnam subsidiary effective 9th May'25.
Original exchange filing (PDF)
More announcements from Dr Reddys Laboratories Ltd
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 14 Nov 2026
- Intimation of Analyst meet · 11 Nov 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 05 Nov 2026
- Allotment of Employee Stock options · 04 Nov 2026
- Clarification - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 04 Nov 2026
- The Exchange has sought Clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.firstpost.com dated November 03, 2026 (Link : https://www.firstpost.com/business/indias-dr-reddys-gets-us-nod-for-40-generic-hiv-prevention-shot-for-120-poorer-countries-14057224.html) .... · 03 Nov 2026
- Transcript of Earnings call · 30 Oct 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 28 Oct 2026
